Roivant Sciences (ROIV) Competitors $10.01 -0.07 (-0.69%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$9.97 -0.04 (-0.40%) As of 04/3/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ROIV vs. ONC, BNTX, TEVA, SMMT, ITCI, GMAB, RDY, MRNA, VTRS, and ASNDShould you be buying Roivant Sciences stock or one of its competitors? The main competitors of Roivant Sciences include Beigene (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Viatris (VTRS), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry. Roivant Sciences vs. Beigene BioNTech Teva Pharmaceutical Industries Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Moderna Viatris Ascendis Pharma A/S Beigene (NASDAQ:ONC) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations, community ranking and valuation. Do institutionals & insiders have more ownership in ONC or ROIV? 48.5% of Beigene shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 7.4% of Beigene shares are held by insiders. Comparatively, 7.9% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community favor ONC or ROIV? Roivant Sciences received 51 more outperform votes than Beigene when rated by MarketBeat users. Likewise, 78.26% of users gave Roivant Sciences an outperform vote while only 60.00% of users gave Beigene an outperform vote. CompanyUnderperformOutperformBeigeneOutperform Votes360.00% Underperform Votes240.00% Roivant SciencesOutperform Votes5478.26% Underperform Votes1521.74% Does the media prefer ONC or ROIV? In the previous week, Beigene had 1 more articles in the media than Roivant Sciences. MarketBeat recorded 10 mentions for Beigene and 9 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.36 beat Beigene's score of 0.33 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beigene 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ONC or ROIV? Beigene presently has a consensus price target of $310.00, indicating a potential upside of 17.28%. Roivant Sciences has a consensus price target of $17.50, indicating a potential upside of 74.83%. Given Roivant Sciences' higher possible upside, analysts plainly believe Roivant Sciences is more favorable than Beigene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beigene 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more volatility & risk, ONC or ROIV? Beigene has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Is ONC or ROIV more profitable? Beigene has a net margin of -25.94% compared to Roivant Sciences' net margin of -119.54%. Roivant Sciences' return on equity of -14.05% beat Beigene's return on equity.Company Net Margins Return on Equity Return on Assets Beigene-25.94% -25.12% -14.95% Roivant Sciences -119.54%-14.05%-12.81% Which has stronger valuation and earnings, ONC or ROIV? Roivant Sciences has lower revenue, but higher earnings than Beigene. Roivant Sciences is trading at a lower price-to-earnings ratio than Beigene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeigene$3.81B6.84-$881.71M-$6.14-43.05Roivant Sciences$122.59M58.27$4.35B-$0.15-66.73 SummaryRoivant Sciences beats Beigene on 13 of the 18 factors compared between the two stocks. Remove Ads Get Roivant Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ROIV vs. The Competition Export to ExcelMetricRoivant SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.14B$6.73B$5.54B$7.49BDividend YieldN/A2.79%4.86%4.04%P/E Ratio-66.736.9923.2518.07Price / Sales58.27198.60361.2686.83Price / CashN/A65.6738.1634.64Price / Book1.295.926.493.99Net Income$4.35B$142.37M$3.21B$247.18M7 Day Performance-4.48%-9.32%-6.42%-6.42%1 Month Performance-1.57%-10.26%-0.68%-7.44%1 Year Performance-13.03%-15.08%6.05%-4.31% Roivant Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ROIVRoivant Sciences2.3695 of 5 stars$10.01-0.7%$17.50+74.8%-13.0%$7.14B$122.59M-66.73860Positive NewsGap DownONCBeigene1.2959 of 5 stars$272.17+1.8%$310.00+13.9%N/A$26.85B$3.81B-33.0310,600Insider TradeNews CoverageGap DownBNTXBioNTech2.734 of 5 stars$91.06-4.1%$143.73+57.8%+1.4%$21.85B$2.75B-43.363,080Analyst ForecastHigh Trading VolumeTEVATeva Pharmaceutical Industries2.3135 of 5 stars$15.39+2.0%$23.43+52.3%+5.1%$17.44B$16.54B-10.6136,800Analyst UpgradeShort Interest ↑Gap DownSMMTSummit Therapeutics2.7277 of 5 stars$19.29-5.1%$35.44+83.7%+378.7%$14.23B$700,000.00-68.89110Gap DownITCIIntra-Cellular Therapies3.5421 of 5 stars$131.92+0.1%$106.08-19.6%N/A$14.05B$680.50M-151.63560Analyst ForecastNews CoveragePositive NewsHigh Trading VolumeGMABGenmab A/S3.8151 of 5 stars$19.58-1.6%$41.33+111.1%-34.3%$12.96B$21.53B11.251,660Analyst DowngradeRDYDr. Reddy's Laboratories3.3037 of 5 stars$13.19-0.1%$17.00+28.9%-9.5%$11.01B$311.31B21.0024,800Positive NewsMRNAModerna4.2773 of 5 stars$28.35-8.9%$59.00+108.1%-74.6%$10.96B$3.20B-3.053,900High Trading VolumeVTRSViatris2.6252 of 5 stars$8.71+0.3%$10.50+20.6%-32.1%$10.40B$14.74B-11.7737,000ASNDAscendis Pharma A/S3.023 of 5 stars$155.86+0.8%$204.64+31.3%+0.4%$9.46B$363.64M-21.951,017Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies ONC Competitors BNTX Competitors TEVA Competitors SMMT Competitors ITCI Competitors GMAB Competitors RDY Competitors MRNA Competitors VTRS Competitors ASND Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ROIV) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Roivant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
